Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 31;8(12):e024502.
doi: 10.1136/bmjopen-2018-024502.

Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients

Affiliations

Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients

Michele F Eisenga et al. BMJ Open. .

Abstract

Introduction: In the past decades, short-term results after solid organ transplantation have markedly improved. Disappointingly, this has not been accompanied by parallel improvements in long-term outcomes after transplantation. To improve graft and recipient outcomes, identification of potentially modifiable risk factors and development of biomarkers are required. We provide the rationale and design of a large prospective cohort study of solid organ transplant recipients (TransplantLines).

Methods and analysis: TransplantLines is designed as a single-centre, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. Data will be collected from transplant candidates before transplantation, during transplantation, at 3 months, 6 months, 1 year, 2 years and 5 years, and subsequently every 5 years after transplantation. Data from living organ donors will be collected before donation, during donation, at 3 months, 1 year and 5 years after donation, and subsequently every 5 years. The primary outcomes are mortality and graft failure. The secondary outcomes will be cause-specific mortality, cause-specific graft failure and rejection. The tertiary outcomes will be other health problems, including diabetes, obesity, hypertension, hypercholesterolaemia and cardiovascular disease, and disturbances that relate to quality of life, that is, physical and psychological functioning, including quality of sleep, and neurological problems such as tremor and polyneuropathy.

Ethics and dissemination: Ethical approval has been obtained from the relevant local ethics committee. The TransplantLines cohort study is designed to deliver pioneering insights into transplantation and donation outcomes. The study design allows comprehensive data collection on perioperative care, nutrition, social and psychological functioning, and biochemical parameters. This may provide a rationale for future intervention strategies to more individualised, patient-centred transplant care and individualisation of treatment.

Trial registration number: NCT03272841.

Keywords: cohort study; survival; transplant medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Overview of different health problems that arise in the long term after transplantation, physical, psychological and social.
Figure 2
Figure 2
Flow chart of the different visits in the TransplantLines study. At every study visit, biobank, general tests and questionnaires will be performed. Specifically addition at each timepoints; at time of transplantation, perioperative residual material will be collected. At 3 months after transplantation, cognitive protocol will be performed. At 6 months, physical protocol will be carried out. At 12 months, randomisation to physical or cognitive protocol will occur. At 2 years after transplantation, a limited set of tests will be executed. Follow-up will be performed every 5 years.
Figure 3
Figure 3
Overview of the three main pillars of the TransplantLines study, that is, questionnaires, biobank and tests. The collection of data in these pillars at multiple timepoints will allow investigation of whether biomarkers at baseline can better predict the occurrence of adverse outcomes and whether correction could possibly result in an improved survival.

Similar articles

Cited by

References

    1. Kirk R, Dipchand AI, Edwards LB, et al. . The registry of the international society for heart and lung transplantation: fifteenth pediatric heart transplantation report–2012. J Heart Lung Transplant 2012;31:1065–72. 10.1016/j.healun.2012.08.001 - DOI - PubMed
    1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450–62. 10.1111/j.1600-6143.2010.03283.x - DOI - PubMed
    1. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011;11:1226–35. 10.1111/j.1600-6143.2011.03539.x - DOI - PubMed
    1. Dharnidharka VR, Lamb KE, Zheng J, et al. . Lack of significant improvements in long-term allograft survival in pediatric solid organ transplantation: A US national registry analysis. Pediatr Transplant 2015;19:477–83. 10.1111/petr.12465 - DOI - PubMed
    1. Hariharan S, Johnson CP, Bresnahan BA, et al. . Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605–12. 10.1056/NEJM200003023420901 - DOI - PubMed

Publication types

Associated data